Impetigo: Diagnosis and Treatment

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2014 Aug 15;90(4):229-235.

  Patient information: See related handout on impetigo, written by the authors of this article.

Author disclosure: No relevant financial affiliations.

Impetigo is the most common bacterial skin infection in children two to five years of age. There are two principal types: nonbullous (70% of cases) and bullous (30% of cases). Nonbullous impetigo, or impetigo contagiosa, is caused by Staphylococcus aureus or Streptococcus pyogenes, and is characterized by honey-colored crusts on the face and extremities. Impetigo primarily affects the skin or secondarily infects insect bites, eczema, or herpetic lesions. Bullous impetigo, which is caused exclusively by S. aureus, results in large, flaccid bullae and is more likely to affect intertriginous areas. Both types usually resolve within two to three weeks without scarring, and complications are rare, with the most serious being poststreptococcal glomerulonephritis. Treatment includes topical antibiotics such as mupirocin, retapamulin, and fusidic acid. Oral antibiotic therapy can be used for impetigo with large bullae or when topical therapy is impractical. Amoxicillin/clavulanate, dicloxacillin, cephalexin, clindamycin, doxycycline, minocycline, trimethoprim/sulfamethoxazole, and macrolides are options, but penicillin is not. Natural therapies such as tea tree oil; olive, garlic, and coconut oils; and Manuka honey have been anecdotally successful, but lack sufficient evidence to recommend or dismiss them as treatment options. Treatments under development include minocycline foam and Ozenoxacin, a topical quinolone. Topical disinfectants are inferior to antibiotics and should not be used. Empiric treatment considerations have changed with the increasing prevalence of antibiotic-resistant bacteria, with methicillin-resistant S. aureus, macrolide-resistant streptococcus, and mupirocin-resistant streptococcus all documented. Fusidic acid, mupirocin, and retapamulin cover methicillin-susceptible S. aureus and streptococcal infections. Clindamycin proves helpful in suspected methicillin-resistant S. aureus infections. Trimethoprim/sulfamethoxazole covers methicillin-resistant S. aureus infection, but is inadequate for streptococcal infection.

Impetigo is a common bacterial skin infection caused by Staphylococcus aureus, group A beta-hemolytic Streptococcus pyogenes, a combination of the two, or less commonly, anaerobic bacteria.1,2 In the United States, more than 11 million skin and soft tissue infections are caused by S. aureus annually.3 Impetigo is the most common skin infection in children two to five years of age, but persons of any age can be affected.4 One-third of skin and soft tissue infections in returning travelers are attributable to impetigo, usually secondary to infected mosquito bites.5

View/Print Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

Topical antibiotics are more effective than placebo and preferable to oral antibiotics for limited impetigo.

A

8, 11

Oral penicillin should not be used for impetigo because it is less effective than other antibiotics.

B

8, 12

Oral erythromycin and macrolides should not be used to treat impetigo because of emerging drug resistance.

B

8, 12

There is insufficient evidence to recommend topical disinfectants for the treatment of impetigo.

B

8

There is insufficient evidence to recommend (or dismiss) popular herbal treatments for impetigo.

C

24


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

Topical antibiotics are more effective than placebo and preferable to oral antibiotics for limited impetigo.

A

8, 11

Oral penicillin should not be used for impetigo because it is less effective than other antibiotics.

B

8, 12

Oral erythromycin and macrolides should not be used to treat impetigo because of emerging drug resistance.

B

8, 12

There is insufficient evidence to recommend topical disinfectants for the treatment of impetigo.

B

8

There is insufficient evidence to recommend (or dismiss) popular herbal treatments for impetigo.

C

24


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

Many bacteria inhabit healthy skin; some types, such as S. pyogenes and S. aureus, intermittently colonize the nasal, axillary, pharyngeal, or perineal areas.2,6 These bacteria can lead to infection of susceptible skin.6 Other factors that predispose to impetigo are skin trauma; hot, humid climates; poor hygiene; day care settings; crowding; malnutrition; and diabetes mellitus or other medical comorbidities.2,6 Autoinoculation via fingers, towels, or clothing often leads to the formation of satellite lesions in adjacent areas.6 The highly contagious nature of impetigo also allows spread from patients to close contacts. Although impetigo is considered a self-limited infection, antibiotic treatment is often initiated for a quicker cure and to prevent the spread to others.2 This can help decrease the number of school and work days lost.6 Hygienic practices such as cleaning minor injuries with soap and water, handwashing, regular bathing, and avoiding contact with infected children can help prevent infection.7

Clinical Presentation

There are two presentations of impetigo: nonbullous (also known as impetigo contagiosa) and bullous.

NONBULLOUS

Nonbullous impetigo is the most common presentation, comprising 70% of cases. Nonbullous impetigo can be further classified as primary or the more prevalent secondary (common) form.4,8 Primary impetigo is a direct bacterial invasion of intact healthy skin.4,8 Secondary (common) impetigo is a bacterial infection of disrupted skin caused by trauma, eczema, insect bites, scabies, or herpetic outbreaks and other diseases.6 Diabetes or other underlying systemic conditions also increase susceptibility.6 Impetigo starts as maculopapular lesions that transition into thin-walled vesicles that rapidly rupture, leaving superficial, sometimes pruritic or painful erosions covered by the classic honey-colored crusts4,8 (Figure 1). The course of infection can last two to three weeks if untreated.8 Once the crust dries, the remaining area heals without scarring. The exposed skin of the face (e.g., nares, perioral region) and the extremities are the most commonly affected sites.1 Regional lymphadenitis may occur, but systemic symptoms are unlikely.1,8 Nonbullous impetigo is usually caused by S. aureus, but S. pyogenes can also be involved, especially in warmer, more humid climates.

View/Print Figure

Figure 1.

Honey-colored crust of nonbullous impetigo.

Copyright © Logical Images, Inc.


Figure 1.

Honey-colored crust of nonbullous impetigo.

Copyright © Logical Images, Inc.

BULLOUS

Bullous impetigo is caused only by S. aureus1,4,9 and is characterized by large, fragile, flaccid bullae that can rupture and ooze yellow fluid (Figure 24). It usually resolves within two to three weeks without scarring.8 The pathognomonic collarette of scales on its periphery develops after the bullae rupture, leaving a thin, brown crust on the remaining erosions1(Figure 3). These larger bullae form because of exfoliative toxins produced by S. aureus strains that cause loss of cell adhesion in the superficial epidermis.9 Bullous impetigo is typically found on the trunk, axilla, and extremities, and in intertriginous (diaper) areas.2 It is the most common cause of ulcerative rash on the buttocks of infants.1 Systemic symptoms are uncommon but can include fever, diarrhea, and weakness.4

View/Print Figure

Figure 2.

Flaccid bullae that ooze yellow fluid in a patient with impetigo.

Reprinted with permission from Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):862.


Figure 2.

Flaccid bullae that ooze yellow fluid in a patient with impetigo.

Reprinted with permission from Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):862.

View/Print Figure

Figure 3.

Brown crust appearing after bullae rupture in a patient with impetigo.

Copyright © Logical Images, Inc.


Figure 3.

Brown crust appearing after bullae rupture in a patient with impetigo.

Copyright © Logical Images, Inc.

Diagnosis

The diagnosis of nonbullous and bullous impetigo is nearly always clinical. Differential diagnosis includes many other blistering and rash disorders (Table 1).1,4,10 Skin swabs cannot differentiate between bacterial infection and colonization.11 In patients in whom first-line therapy fails, culture of the pus or bullous fluid, not the intact skin, may be helpful for pathogen identification and antimicrobial susceptibilities.12 Although serologic testing for streptococcal antibodies is helpful in the diagnosis of acute poststreptococcal glomerulonephritis, it does not aid in the diagnosis of impetigo.13

View/Print Table

Table 1.

Differential Diagnosis of Impetigo

Bullous

Bullous erythema multiforme

Bullous fixed drug eruption

Bullous lupus erythematosus

Bullous pemphigoid reactions

Bullous scabies

Contact dermatitis

Dermatitis herpetiformis

Insect bites

Linear immunoglobulin A bullous dermatosis

Necrotizing fasciitis

Pemphigus vulgaris

Stevens-Johnson syndrome

Thermal burns

Transient neonatal pustular melanosis

Nonbullous

Atopic dermatitis

Bockhart impetigo*10

Childhood discoid lupus erythematosus

Contact dermatitis

Cutaneous candidiasis

Dermatophytosis (tinea corporis or capitis)

Herpes simplex virus

Pediculosis (lice)

Scabies

Sweet syndrome (acute febrile neutrophilic dermatosis)

Varicella zoster virus


*—A pustular folliculitis, not true impetigo.

Information from references 1, 4, and 10.

Table 1.

Differential Diagnosis of Impetigo

Bullous

Bullous erythema multiforme

Bullous fixed drug eruption

Bullous lupus erythematosus

Bullous pemphigoid reactions

Bullous scabies

Contact dermatitis

Dermatitis herpetiformis

Insect bites

Linear immunoglobulin A bullous dermatosis

Necrotizing fasciitis

Pemphigus vulgaris

Stevens-Johnson syndrome

Thermal burns

Transient neonatal pustular melanosis

Nonbullous

Atopic dermatitis

Bockhart impetigo*10

Childhood discoid lupus erythematosus

Contact dermatitis

Cutaneous candidiasis

Dermatophytosis (tinea corporis or capitis)

Herpes simplex virus

Pediculosis (lice)

Scabies

Sweet syndrome (acute febrile neutrophilic dermatosis)

Varicella zoster virus


*—A pustular folliculitis, not true impetigo.

Information from references 1, 4, and 10.

Complications

Impetigo is usually a self-limited condition, and although rare, complications can occur. These include cellulitis (nonbullous form), septicemia, osteomyelitis, septic arthritis, lymphangitis, lymphadenitis, guttate psoriasis, staphylococcal scalded skin syndrome, and acute poststreptococcal glomerulonephritis, with poststreptococcal glomerulonephritis being the most serious.14 The number of possible causes, incidence, and clinical severity of acute poststreptococcal glomerulonephritis have decreased, because the causative organism of impetigo has shifted from S. pyogenes to S. aureus.13 Most cases of poststreptococcal glomerulonephritis in the United States are associated with pharyngitis. The strains of S. pyogenes implicated in impetigo are thought to have minimal nephritogenic potential.13 There are no data to indicate that antibiotic treatment of impetigo has any effect on preventing the development of acute poststreptococcal glomerulonephritis, which can occur in up to 5% of patients with nonbullous impetigo.1,11,15,16 Rheumatic fever does not appear to be a complication of impetigo.16

Treatment

Treatment options for impetigo include topical antibiotics, systemic antibiotics, and topical disinfectants.8 Quality evidence-based research for the most effective treatment of impetigo is lacking.11 In 2012, an updated Cochrane review on impetigo interventions evaluated 68 randomized controlled trials, including 26 on oral treatments and 24 on topical treatments. There was no clear evidence as to which intervention is most effective.8 Topical antibiotics are more effective than placebo and preferable to oral antibiotics for limited impetigo.8,11 Systemic antibiotics are often reserved for more generalized or severe infections in which topical therapy is not practical. Clinicians sometimes may choose both topical and systemic therapy.8 The ideal treatment should be effective, be inexpensive, have limited adverse effects, and should not promote bacterial resistance.2,4,8

TOPICAL ANTIBIOTICS

Topical antibiotics (Table 2 6,8,11,14,1719) have the advantage of being applied only where needed, minimizing antibiotic resistance and avoiding gastrointestinal and other systemic adverse effects.4,8 The length of time of topical treatment varies based on product, but in clinical trials, a seven-day course was more effective than placebo for resolution of impetigo.8,11 Local allergic reactions, skin sensitization, and difficulty with application to areas such as eyelids, mouth, and back are potential disadvantages of topical treatments. Three topical antibiotic preparations recommended for impetigo are mupirocin 2% cream or ointment (Bactroban), retapamulin 1% ointment (Altabax), and fusidic acid (not available in United States). Empiric treatment considerations have changed with the increasing prevalence of antibiotic-resistant bacteria. Methicillin-resistant S. aureus (MRSA), macrolide-resistant streptococcus, and mupirocin-resistant streptococcus are now documented.6,14

View/Print Table

Table 2.

Topical Antibiotics for Impetigo

MedicationInstructionsCost*

Fusidic acid 2% ointment†17

Apply to affected skin three times daily for seven to 12 days

Available in Canada and Europe

Mupirocin 2% cream (Bactroban)‡8,18

Apply to affected skin three times daily for seven to 10 days; reevaluate after three to five days if no clinical response

Approved for use in persons older than three months

15-g tube: $48 ($89)

30-g tube: $50 ($144)

Mupirocin 2% ointment‡11

Apply to affected skin three times daily for seven to 14 days

Dosing in children is same as adults

Approved for use in persons older than two months

22-g tube: $14 ($103)

Retapamulin 1% ointment (Altabax)§19

Apply to affected skin twice daily for five days

Total treatment area should not exceed 100 cm2 in adults or 2% of total body surface area in children

Approved for use in persons nine months or older

15-g tube: NA ($130)

30-g tube: NA ($245)


NA = not available.

*—Estimated retail price based on information obtained at http://www.goodrx.com (accessed April 7, 2014). Generic price listed first; brand listed in parentheses.

†—Coverage for Staphylococcus aureus (methicillin-susceptible) and streptococcus.

‡—Coverage for S. aureus (methicillin-susceptible) and streptococcus. Mupirocin-resistant streptococcus has now been documented.6,14

§—First member of the pleuromutilin class of antibiotics. Coverage for S. aureus (methicillin-susceptible) and streptococcus.19

Information from references 6, 8, 11, 14, and 17 through 19.

Table 2.

Topical Antibiotics for Impetigo

MedicationInstructionsCost*

Fusidic acid 2% ointment†17

Apply to affected skin three times daily for seven to 12 days

Available in Canada and Europe

Mupirocin 2% cream (Bactroban)‡8,18

Apply to affected skin three times daily for seven to 10 days; reevaluate after three to five days if no clinical response

Approved for use in persons older than three months

15-g tube: $48 ($89)

30-g tube: $50 ($144)

Mupirocin 2% ointment‡11

Apply to affected skin three times daily for seven to 14 days

Dosing in children is same as adults

Approved for use in persons older than two months

22-g tube: $14 ($103)

Retapamulin 1% ointment (Altabax)§19

Apply to affected skin twice daily for five days

Total treatment area should not exceed 100 cm2 in adults or 2% of total body surface area in children

Approved for use in persons nine months or older

15-g tube: NA ($130)

30-g tube: NA ($245)


NA = not available.

*—Estimated retail price based on information obtained at http://www.goodrx.com (accessed April 7, 2014). Generic price listed first; brand listed in parentheses.

†—Coverage for Staphylococcus aureus (methicillin-susceptible) and streptococcus.

‡—Coverage for S. aureus (methicillin-susceptible) and streptococcus. Mupirocin-resistant streptococcus has now been documented.6,14

§—First member of the pleuromutilin class of antibiotics. Coverage for S. aureus (methicillin-susceptible) and streptococcus.19

Information from references 6, 8, 11, 14, and 17 through 19.

Retapamulin is a novel pleuromutilin antibacterial and the first new topical antibacterial in nearly 20 years.14 Pleuromutilins, derived from the fungus Clitopilus passeckerianus, have antibacterial activity against gram-positive bacterial organisms.20 Retapamulin acts on three key aspects of bacterial protein synthesis, making it far less likely to induce resistant strains. In 2007, the U.S. Food and Drug Administration approved retapamulin 1% ointment for the treatment of impetigo due to S. aureus (methicillin-susceptible isolates only) or S. pyogenes in adults and children at least nine months of age. Retapamulin is not approved for intranasal staphylococcal carrier treatment or treatment of MRSA-related skin infections.6,19  Pricing of the two topical treatment options available in the United States varies depending on preparation. Mupirocin is available as a less expensive generic version and as a brand. All available mupirocin products are less expensive than the newer brand-only retapamulin ointment (Table 2 6,8,11,14,1719).

ORAL ANTIBIOTICS

Oral antibiotic therapy can be used for impetigo with large bullae or when topical therapy is impractical (Table 3).12,15 Treatment for seven days is usually sufficient, but this can be extended if the clinical response is inadequate and antibacterial susceptibility has been confirmed. There is no clear evidence-based preference among the different classes of oral antibiotics. Comparison studies also show no significant difference in cure rates between topical and oral antibiotics.8 In the past, erythromycin and penicillin were standard treatments, but because of emerging drug resistance, they are no longer routinely used.12 Resistance rates vary regionally, so health care professionals should check local resistance patterns to select the appropriate antibiotic.8 One study that lacked statistical power showed oral penicillin V potassium was no more effective than placebo.4,11 In other studies, penicillin V potassium was inferior to erythromycin and cloxacillin (no longer available in the United States), whereas topical mupirocin was slightly superior to oral erythromycin. No macrolide was found to be better than another, but all were found superior to penicillin V potassium; however, because of increasing macrolide resistance, they are no longer a preferred option. Amoxicillin/clavulanate (Augmentin) was superior to amoxicillin alone because of its coverage of β-lactamase–producing organisms. Although cephalosporins may be used, there is no evidence that one generation is better than another.8

View/Print Table

Table 3.

Systemic Antibiotics for Impetigo

DrugAdult seven-day doseCost (for a typical course of treatment)*Children seven-day doseCost*

Amoxicillin/clavulanate (Augmentin)†

875/125 mg every 12 hours

$19 ($193)

Younger than three months: 30 mg per kg per day

Three months or older: 25 to 45 mg per kg per day for those weighing less than 40 kg (88 lb); 875/125 mg every 12 hours for those weighing 40 kg or more

Based on mg per kg per day of the amoxicillin component in divided doses every 12 hours

1 bottle, 400/57 mg per 5 mL (100-mL oral suspension): $30 ($125)

Cephalexin (Keflex)

250 mg every six hours or 500 mg every 12 hours

$5 ($90)

25 to 50 mg per kg per day in divided doses every six to 12 hours

1 bottle, 250 mg per 5 mL (100-mL oral suspension): $14 (NA)

Clindamycin‡

300 to 600 mg every six to eight hours

$18 ($200)

10 to 25 mg per kg per day in divided doses every six to eight hours

1 bottle, 75 mg per 5 mL (100-mL oral solution): $47 (pricing varies by region)

Dicloxacillin

250 mg every six hours

$14 (NA)

12.5 to 25 mg per kg per day in divided doses every six hours

See adult pricing: no liquid formulation available

Doxycycline§

50 to 100 mg every 12 hours

$15 ($95)

2.2 to 4.4 mg per kg per day in divided doses every 12 hours

Not recommend in children younger than eight years

1 bottle, 25 mg per 5 mL (60-mL oral suspension): $20 (pricing varies by region)

Minocycline (Minocin)§

100 mg every 12 hours

$36 ($185)

Loading dose of 4 mg per kg for first dose (maximum dose of 200 mg), then 4 mg per kg per day in divided doses every 12 hours

Maximum of 400 mg per day

Not recommend in children younger than eight years

See adult pricing: no liquid formulation available

Trimethoprim/sulfamethoxazole§

160/800 mg every 12 hours

$4 (NA)

8 to 10 mg per kg per day based on the trimethoprim component in divided doses every 12 hours

1 bottle, 40/200 mg per 5 mL (100-mL oral suspension): $4 (pricing varies by region)


note: Because of emerging resistance, penicillin and erythromycin are no longer recommended treatments.12

NA = not available.

*—Estimated retail price based on information obtained at http://www.goodrx.com (accessed April 7, 2014). Generic price listed first; brand listed in parentheses.

†—Good coverage for Staphylococcus aureus (methicillin-susceptible) and streptococcus.

‡—If methicillin-resistant S. aureus is suspected or proven.

§—If methicillin-resistant S. aureus is suspected or proven. There is no activity against streptococcus.

Information from references 12 and 15.

Table 3.

Systemic Antibiotics for Impetigo

DrugAdult seven-day doseCost (for a typical course of treatment)*Children seven-day doseCost*

Amoxicillin/clavulanate (Augmentin)†

875/125 mg every 12 hours

$19 ($193)

Younger than three months: 30 mg per kg per day

Three months or older: 25 to 45 mg per kg per day for those weighing less than 40 kg (88 lb); 875/125 mg every 12 hours for those weighing 40 kg or more

Based on mg per kg per day of the amoxicillin component in divided doses every 12 hours

1 bottle, 400/57 mg per 5 mL (100-mL oral suspension): $30 ($125)

Cephalexin (Keflex)

250 mg every six hours or 500 mg every 12 hours

$5 ($90)

25 to 50 mg per kg per day in divided doses every six to 12 hours

1 bottle, 250 mg per 5 mL (100-mL oral suspension): $14 (NA)

Clindamycin‡

300 to 600 mg every six to eight hours

$18 ($200)

10 to 25 mg per kg per day in divided doses every six to eight hours

1 bottle, 75 mg per 5 mL (100-mL oral solution): $47 (pricing varies by region)

Dicloxacillin

250 mg every six hours

$14 (NA)

12.5 to 25 mg per kg per day in divided doses every six hours

See adult pricing: no liquid formulation available

Doxycycline§

50 to 100 mg every 12 hours

$15 ($95)

2.2 to 4.4 mg per kg per day in divided doses every 12 hours

Not recommend in children younger than eight years

1 bottle, 25 mg per 5 mL (60-mL oral suspension): $20 (pricing varies by region)

Minocycline (Minocin)§

100 mg every 12 hours

$36 ($185)

Loading dose of 4 mg per kg for first dose (maximum dose of 200 mg), then 4 mg per kg per day in divided doses every 12 hours

Maximum of 400 mg per day

Not recommend in children younger than eight years

See adult pricing: no liquid formulation available

Trimethoprim/sulfamethoxazole§

160/800 mg every 12 hours

$4 (NA)

8 to 10 mg per kg per day based on the trimethoprim component in divided doses every 12 hours

1 bottle, 40/200 mg per 5 mL (100-mL oral suspension): $4 (pricing varies by region)


note: Because of emerging resistance, penicillin and erythromycin are no longer recommended treatments.12

NA = not available.

*—Estimated retail price based on information obtained at http://www.goodrx.com (accessed April 7, 2014). Generic price listed first; brand listed in parentheses.

†—Good coverage for Staphylococcus aureus (methicillin-susceptible) and streptococcus.

‡—If methicillin-resistant S. aureus is suspected or proven.

§—If methicillin-resistant S. aureus is suspected or proven. There is no activity against streptococcus.

Information from references 12 and 15.

The incidence of MRSA-related skin and soft tissue infections was increasing, but more recent studies show it may be declining.21 No studies have specifically identified a problem with MRSA-related impetigo in adults or children, but cultures may still be useful in some settings.6,12 If MRSA infection is suspected, initial treatment with trimethoprim/sulfamethoxazole, clindamycin, or a tetracycline (doxycycline or minocycline [Minocin]) is recommended pending culture results.6 Although trimethoprim/sulfamethoxazole is effective for S. aureus infection, including most MRSA infections, its use for impetigo is limited by inadequate coverage of streptococcal bacteria. Oral clindamycin penetrates skin and skin structures and should be considered if MRSA infection is suspected. Because of an increasing risk of pseudomembranous colitis, clindamycin should be reserved for patients allergic to penicillin, or for infections that fail to respond to other treatments. Tetracyclines can be used for susceptible MRSA infections, but should be avoided in children younger than eight years.12 Oral fluoroquinolones are not preferred because of low staphylococcal activity and their potential association with tendinopathy and arthropathies.12

TOPICAL DISINFECTANTS

There are some studies on the benefits of nonantibiotic treatments, such as disinfectant soaps, but they lack statistical power.11 Disinfectants appear to be less effective than topical antibiotics and are not recommended.8 Studies comparing hexachlorophene (not available in the United States) with bacitracin and hydrogen peroxide with topical fusidic acid found the topical antibiotic to be more effective.8,22,23

NATURAL THERAPIES

The evidence is insufficient to recommend or dismiss popular herbal treatments for impetigo.24 Natural remedies such as tea tree oil; tea effusions; olive, garlic, and coconut oils; and Manuka honey have been anecdotally successful. The fact that impetigo is self-limited means that many “cures” could appear to be helpful without being superior to placebo. In one study, tea leaf ointment and oral cephalexin (Keflex) were similarly effective, with a cure rate of 81% vs. 79%.25 Tea tree oil (derived from Melaleuca alternifolia) appeared to be equivalent to mupirocin 2% for topical decolonization of MRSA.26

Future Treatments

Future treatments for impetigo might include minocycline foam (Foamix), which has successfully completed phase II trials, and Ozenoxacin, a topical quinolone that has successfully completed phase III clinical trials.27,28 Few controlled clinical trials have had their results published and most are methodologically weak. This area seems to merit further study through rigorous clinical trials.

Data Sources: A PubMed search was conducted for impetigo-related topics, including clinical reviews, randomized controlled trials, and meta-analyses. Search terms included impetigo; impetigo and treatment; retapamulin; fusidic acid; impetigo and MRSA; natural and herbal treatments for impetigo; minocycline foam (Foamix); Ozenoxacin; antibiotic resistance and impetigo; and topical and systemic treatments for impetigo. Relevant publications from the Cochrane Database of Systematic Reviews, Essential Evidence, UpToDate, Epocrates, and the Centers for Disease Control and Prevention website were also reviewed. Search dates: April to December 2012, and May 2014.

The Authors

show all author info

HOLLY HARTMAN-ADAMS, MD, is an assistant professor of emergency medicine at West Virginia University Robert C. Byrd Health Sciences Center in Morgantown....

CHRISTINE BANVARD, MD, is an assistant professor of emergency medicine at West Virginia University Robert C. Byrd Health Sciences Center.

GREGORY JUCKETT, MD, MPH, is a professor of family medicine and director of the International Travel Clinic at West Virginia University Robert C. Byrd Health Sciences Center.

Author disclosure: No relevant financial affiliations.

Address correspondence to Holly Hartman-Adams, MD, West Virginia University Robert C. Byrd Health Sciences Center, P.O. Box 9247, Morgantown, WV 26506 (e-mail: hhartman@hsc.wvu.edu). Reprints are not available from the authors.

REFERENCES

show all references

1. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol. 2003;42(4):251–255....

2. Feaster T, Singer JI. Topical therapies for impetigo. Pediatr Emerg Care. 2010;26(3):222–227, quiz 228–231.

3. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12(11):1715–1723.

4. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859–864.

5. Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg. 2009;80(3):431–434.

6. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012;29(3):243–248.

7. Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet. 2005;366(9481):225–233.

8. Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;(1):CD003261.

9. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol. 2002;118(5):845–850.

10. Hsu S, Halmi BH. Bockhart's impetigo: complication of waterbed use. Int J Dermatol. 1999;38(10):769–770.

11. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53(491):480–487.

12. Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila). 2008;47(3):211–219.

13. Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol. 2008;23(7):1101–1106.

14. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol. 2010;9(10):1198–1204.

15. Stevens DL, Bisno AL, Chambers HF, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published corrections appear in Clin Infect Dis. 2006;42(8):1219 and Clin Infect Dis. 2005;41(12):1830]. Clin Infect Dis. 2005;41(10):1373–1406.

16. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334(4):240–245.

17. Koning S, van Suijlekom-Smit LW, Nouwen JL, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002;324(7331):203–206.

18. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292.

19. Altabax (retapamulin) ointment [package insert]. Research Triangle Park, N.C.: GlaxoSmithKline; 2010. https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductDetailPage&product_id=1320843776888&featureKey=603182. Accessed May 5, 2014.

20. Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek RR. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 2006;50(11):3875–3881.

21. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005–2010. JAMA. 2012;308(1):50–59.

22. Ruby RJ, Nelson JD. The influence of hexachlorophene scrubs on the response to placebo or penicillin therapy in impetigo. Pediatrics. 1973;52(6):854–859.

23. Christensen OB, Anehus S. Hydrogen peroxide cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta Derm Venereol. 1994;74(6):460–462.

24. Martin KW, Ernst E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother. 2003;51(2):241–246.

25. Sharquie KE, al-Turfi IA, al-Salloum SM. The antibacterial activity of tea in vitro and in vivo (in patients with impetigo contagiosa). J Dermatol. 2000;27(11):706–710.

26. Caelli M, Porteous J, Carson CF, Heller R, Riley TV. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2000;46(3):236–237.

27. Foamix's minocycline foam–100% effective in impetigo phase II clinical trial with no side effects. 80% improved significantly after 3 days of treatment. March 14, 2012. http://www.foamix.co.il/news.asp?nodeID=515&itemID=2. Accessed April 2, 2014.

28. Ferrer successfully completes a phase III clinical trial in adult and paediatric patients with impetigo for novel antibacterial compound Ozenoxacin. June 5, 2013. http://www.drugs.com/clinical_trials/ferrer-successfully-completes-phase-i-clinical-trial-adult-paediatric-patients-impetigo-novel-15683.html. Accessed May 8, 2014.



 

Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Sep 15, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article